SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-20-025221
Filing Date
2020-02-05
Accepted
2020-02-05 14:11:05
Documents
2
Group Members
MPM ONCOLOGY IMPACT MANAGEMENT GP LLCMPM ONCOLOGY IMPACT MANAGEMENT LPONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13G d869407dsc13g.htm SC 13G 89515
2 EX-99.A d869407dex99a.htm EX-99.A 10527
  Complete submission text file 0001193125-20-025221.txt   101782
Mailing Address 3611 VALLEY CENTER DRIVE SUITE 500 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTER DRIVE SUITE 500 SAN DIEGO CA 92130 858-792-6300
MEI Pharma, Inc. (Subject) CIK: 0001262104 (see all company filings)

IRS No.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13G | Act: 34 | File No.: 005-79594 | Film No.: 20578194
SIC: 2834 Pharmaceutical Preparations

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 617-425-9200
UBS Oncology Impact Fund L.P. (Filed by) CIK: 0001691428 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G